DE69804273T2 - 5h-Thiazolo[3,2-a]pyrimidinderivate - Google Patents

5h-Thiazolo[3,2-a]pyrimidinderivate

Info

Publication number
DE69804273T2
DE69804273T2 DE69804273T DE69804273T DE69804273T2 DE 69804273 T2 DE69804273 T2 DE 69804273T2 DE 69804273 T DE69804273 T DE 69804273T DE 69804273 T DE69804273 T DE 69804273T DE 69804273 T2 DE69804273 T2 DE 69804273T2
Authority
DE
Germany
Prior art keywords
thiazolo
pyrimidine derivatives
pyrimidine
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69804273T
Other languages
English (en)
Other versions
DE69804273D1 (de
Inventor
Geo Adam
Sabine Kolczewski
Vincent Mutel
Juergen Wichmann
Thomas Johannes Woltering
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE69804273D1 publication Critical patent/DE69804273D1/de
Application granted granted Critical
Publication of DE69804273T2 publication Critical patent/DE69804273T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C07D239/40—One sulfur atom as doubly bound sulfur atom or as unsubstituted mercapto radical
DE69804273T 1997-07-18 1998-07-11 5h-Thiazolo[3,2-a]pyrimidinderivate Expired - Fee Related DE69804273T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97112324 1997-07-18

Publications (2)

Publication Number Publication Date
DE69804273D1 DE69804273D1 (de) 2002-04-25
DE69804273T2 true DE69804273T2 (de) 2002-10-31

Family

ID=8227080

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69804273T Expired - Fee Related DE69804273T2 (de) 1997-07-18 1998-07-11 5h-Thiazolo[3,2-a]pyrimidinderivate

Country Status (33)

Country Link
US (1) US5958931A (de)
EP (1) EP0891978B1 (de)
JP (1) JP3100573B2 (de)
KR (1) KR100296837B1 (de)
CN (1) CN1102596C (de)
AR (1) AR016129A1 (de)
AT (1) ATE214704T1 (de)
AU (1) AU738207B2 (de)
BR (1) BR9802482A (de)
CA (1) CA2243234C (de)
CO (1) CO5210884A1 (de)
CZ (1) CZ288944B6 (de)
DE (1) DE69804273T2 (de)
DK (1) DK0891978T3 (de)
ES (1) ES2172840T3 (de)
HK (1) HK1018439A1 (de)
HR (1) HRP980398B1 (de)
HU (1) HUP9801587A3 (de)
ID (1) ID21824A (de)
IL (1) IL125358A (de)
MA (1) MA26520A1 (de)
NO (1) NO310512B1 (de)
NZ (1) NZ330988A (de)
PE (1) PE97499A1 (de)
PL (1) PL190218B1 (de)
PT (1) PT891978E (de)
RU (1) RU2197493C2 (de)
SI (1) SI0891978T1 (de)
TR (1) TR199801367A3 (de)
TW (1) TW523518B (de)
UY (1) UY25095A1 (de)
YU (1) YU29798A (de)
ZA (1) ZA986250B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1074549B1 (de) * 1999-08-06 2003-11-19 F. Hoffmann-La Roche Ag Tetrahydro-benzo(d)azepine und deren Verwendung als metabotrope Glutamatrezeptor-Antagonisten
AU2002247149B2 (en) * 2001-01-31 2007-10-25 H. Lundbeck A/S Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
CA2451057A1 (en) * 2001-06-14 2002-12-27 Banyu Pharmaceutical Co., Ltd. Novel isoxazolopyridone derivatives and use thereof
US7329662B2 (en) * 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
KR100847160B1 (ko) * 2004-06-21 2008-07-17 에프. 호프만-라 로슈 아게 피라졸로 피리미딘 유도체
AU2005254657B2 (en) * 2004-06-21 2011-03-17 F. Hoffmann-La Roche Ag Pyrrazolo-pyrimidine derivatives
BRPI0607927A2 (pt) 2005-02-11 2009-10-20 Hoffmann La Roche derivados de pirazol-pirimidina
CN101180299B (zh) 2005-03-23 2010-12-15 弗·哈夫曼-拉罗切有限公司 作为mglur2拮抗剂的乙炔基-吡唑并嘧啶衍生物
EP1934214B1 (de) 2005-09-27 2010-04-07 F.Hoffmann-La Roche Ag Oxadiazolylpyrazolopyrimidine als mglur2-antagonisten
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
ES2409215T3 (es) * 2007-09-14 2013-06-25 Janssen Pharmaceuticals, Inc. 4-fenil-1H-piridin-2-onas 1-3-disustituidas
EA019085B1 (ru) 2007-09-14 2014-01-30 Янссен Фармасьютикалз, Инк. 1',3-двузамещенные 4-(арил-х-фенил)-1н-пиридин-2-оны
RU2492170C9 (ru) * 2007-11-14 2013-12-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Имидазо[1,2-а]пиридиновые производные и их применение в качестве положительных аллостерических модуляторов рецепторов mglur2
BRPI0918055A2 (pt) 2008-09-02 2015-12-01 Addex Pharmaceuticals Sa derivados de 3-azabiciclo[3,1,0]hexila como moduladores de receptores metabotrópicos de glutamato.
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
CN102232074B (zh) 2008-11-28 2014-12-03 奥梅-杨森制药有限公司 作为代谢性谷氨酸盐受体调节剂的吲哚和苯并噁嗪衍生物
CN101503414B (zh) * 2009-03-04 2013-10-30 沈阳药科大学 噻唑并[3,2-b]-1,2,4-三嗪衍生物及其应用
ME01573B (me) 2009-05-12 2014-09-20 Addex Pharma Sa DERIVATI 1,2,4-TRIAZOLO[4,3-a]PIRIDINA I NJIHOVA UPOTREBA U TRETMANU ILI PREVENCIJI NEUROLOŠKIH I PSIHIJATRIJSKIH POREMEĆAJA
BRPI1010831A2 (pt) 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JP5852664B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
WO2012062751A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
CN108929336A (zh) * 2013-10-11 2018-12-04 豪夫迈·罗氏有限公司 作为nmda受体活性的调节剂的噻唑并嘧啶酮类
SI3431106T1 (sl) 2014-01-21 2021-03-31 Janssen Pharmaceutica Nv Kombinacije, ki vsebujejo pozitivne alosterične modulatorje metabotropnega glutamatergičnega receptorja podtipa 2 in njihova uporaba
LT3096790T (lt) 2014-01-21 2019-10-10 Janssen Pharmaceutica, N.V. Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
CN116102580A (zh) * 2017-03-31 2023-05-12 巴斯夫欧洲公司 用于防除动物害虫的嘧啶鎓化合物及其混合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3660418A (en) * 1970-03-16 1972-05-02 Sandoz Ag Certain 2 3 5 6-tetrahydroimidazo(2 1-b)thiazoles
EP0524055A1 (de) * 1991-07-19 1993-01-20 Synthelabo Imidazo(2,1-b)benzothiazolderivate, Verfahren zu ihrer Herstellung und ihre therapeutische Verwendung
PL182285B1 (pl) * 1994-08-12 2001-12-31 Lilly Co Eli Syntetyczne aminokwasy oraz ich estry i srodki farmaceutyczne je zawierajace PL PL PL PL PL PL PL
GB9609976D0 (en) * 1996-05-13 1996-07-17 Lilly Industries Ltd Pharmaceutical compounds
WO1998006724A1 (fr) * 1996-08-09 1998-02-19 Yamanouchi Pharmaceutical Co., Ltd. Agonistes du recepteur du glutamate metabotropique

Also Published As

Publication number Publication date
IL125358A (en) 2002-09-12
CN1102596C (zh) 2003-03-05
KR19990013919A (ko) 1999-02-25
TW523518B (en) 2003-03-11
BR9802482A (pt) 2000-03-14
SI0891978T1 (en) 2002-06-30
DK0891978T3 (da) 2002-07-01
ID21824A (id) 1999-07-29
NO310512B1 (no) 2001-07-16
MA26520A1 (fr) 2004-12-20
RU2197493C2 (ru) 2003-01-27
NO983244L (no) 1999-01-19
JP3100573B2 (ja) 2000-10-16
ZA986250B (en) 1999-01-22
PT891978E (pt) 2002-07-31
AU7730298A (en) 1999-01-28
US5958931A (en) 1999-09-28
KR100296837B1 (ko) 2001-10-26
CN1206010A (zh) 1999-01-27
HUP9801587A2 (hu) 1999-11-29
PL190218B1 (pl) 2005-11-30
HRP980398A2 (en) 1999-04-30
HRP980398B1 (en) 2002-06-30
EP0891978B1 (de) 2002-03-20
NO983244D0 (no) 1998-07-14
ATE214704T1 (de) 2002-04-15
TR199801367A2 (xx) 1999-02-22
CA2243234A1 (en) 1999-01-18
HU9801587D0 (en) 1998-09-28
DE69804273D1 (de) 2002-04-25
AU738207B2 (en) 2001-09-13
NZ330988A (en) 1999-03-29
YU29798A (sh) 2001-12-26
HUP9801587A3 (en) 2001-09-28
CO5210884A1 (es) 2002-10-30
AR016129A1 (es) 2001-06-20
HK1018439A1 (en) 1999-12-24
PL327532A1 (en) 1999-02-01
ES2172840T3 (es) 2002-10-01
CA2243234C (en) 2007-09-18
UY25095A1 (es) 2001-01-31
PE97499A1 (es) 1999-10-12
TR199801367A3 (tr) 1999-02-22
JPH1171380A (ja) 1999-03-16
EP0891978A2 (de) 1999-01-20
CZ288944B6 (cs) 2001-10-17
EP0891978A3 (de) 1999-02-03
IL125358A0 (en) 1999-03-12
CZ223998A3 (cs) 1999-02-17

Similar Documents

Publication Publication Date Title
DE69804273D1 (de) 5h-Thiazolo[3,2-a]pyrimidinderivate
DK1220856T3 (da) Pyrazolo[4,3-d]pyrimidinderivater
IS5722A (is) Pýróló [2,3-dl]pírimídín efnasambönd
DE69915675D1 (de) Triazolo[4,5-d]pyrimidin-derivate
ID26698A (id) SENYAWA-SENYAWA PIROLO [2,3-d] PIRIMIDINA
MA26851A1 (fr) Derives de pyrrolo [2,3-d] pyrimidine
ATE256123T1 (de) Pyrimidonderivate
PT1005446E (pt) Derivados de n-aroilfenilalanina
PT1003719E (pt) Derivados microbicidas de n-sulfonil-glicinalquiniloxifenemetilamida
DE69511086T2 (de) Pyrimidinderivate
DE50001191D1 (de) Pyrazolo[4, 3-d]pyrimidine
DE69716901T2 (de) 2,4-diaminopyrimidin-derivate
NO995033D0 (no) 6,7-disubstituerte-4-aminopyrido[2,3-D]pyrimidinforbindelser
NO995035D0 (no) 5,6,7-trisubstituerte-4-aminopyrido[2,3-D]pyrimidinforbindelser
PT1010699E (pt) Derivados de 3-oxadiazolil-1,6-naftiridina-2(h)-ona substituido em 5
EP0954316A4 (de) Pyrimidine derivaten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee